Last reviewed · How we verify
Glycyrrhetinyl Acetate — Competitive Intelligence Brief
unknown
acetoxolone
Corticosteroid 11-beta-dehydrogenase isozyme 2
Gastroenterology
Live · refreshed every 30 min
Target snapshot
Glycyrrhetinyl Acetate (acetoxolone). Acetoxolone works by inhibiting the enzyme that converts cortisol into its inactive form, allowing more cortisol to be available to reduce inflammation.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Glycyrrhetinyl Acetate TARGET | acetoxolone | unknown | acetoxolone | Corticosteroid 11-beta-dehydrogenase isozyme 2 | ||
| Glycyron | glycyrrhizic acid | marketed | glycyrrhizic acid | High mobility group protein B1, Corticosteroid 11-beta-dehydrogenase isozyme 2, Corticosteroid 11-beta-dehydrogenase isozyme 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (acetoxolone class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Glycyrrhetinyl Acetate CI watch — RSS
- Glycyrrhetinyl Acetate CI watch — Atom
- Glycyrrhetinyl Acetate CI watch — JSON
- Glycyrrhetinyl Acetate alone — RSS
- Whole acetoxolone class — RSS
Cite this brief
Drug Landscape (2026). Glycyrrhetinyl Acetate — Competitive Intelligence Brief. https://druglandscape.com/ci/acetoxolone. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing